Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 26875537 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 502 | 26875540 |
US |
5 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 503 | 26875543 |
US |
34 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, ETONOGESTREL AND ETHINYL ESTRADIOL, FISH OIL, TIRZEPATIDE, |
||||
| 504 | 26875570 |
US |
14 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 505 | 26875617 |
US |
14 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 506 | 26875620 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 507 | 26875624 |
US |
1 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 508 | 26875642 |
US |
34 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 509 | 26875652 |
US |
74 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 510 | 26875675 |
US |
4 | 1 |
Dermatitis atopic, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 511 | 26875742 |
US |
1 | |
Dermatitis atopic, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 512 | 26875894 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 513 | 26872892 |
US |
65 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 514 | 26873005 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 515 | 26873260 |
US |
2 | |
Pruritus, Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, CITALOPRAM, CITALOPRAM HYDROBROMIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, RIVAROXABAN, |
||||
| 516 | 26873337 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 517 | 26873340 |
US |
62 | 2 |
Asthma, Dermatitis atopic, Aphonia, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 518 | 26873355 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, BISOPROLOL FUMARATE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, ROSUVASTATIN CALCIUM, VALSARTAN, VALSARTAN ORAL, RIVAROXABAN, |
||||
| 519 | 26873394 |
US |
53 | 2 |
Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 520 | 26873413 |
US |
73 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 521 | 26873415 |
US |
13 | 1 |
Dermatitis atopic, Skin irritation, |
||||
DUPILUMAB, |
||||
| 522 | 26873426 |
US |
43 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 523 | 26873634 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 524 | 26873654 |
US |
1 | |
Sunburn, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 525 | 26873663 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 526 | 26873850 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 527 | 26873854 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 528 | 26873859 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 529 | 26873866 |
US |
60 | 2 |
Dermatitis atopic, Pain, |
||||
DUPILUMAB, |
||||
| 530 | 26873874 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 531 | 26873877 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 532 | 26873894 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 533 | 26873964 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 534 | 26873965 |
US |
54 | 1 |
Dermatitis atopic, Therapeutic response shortened, Rash, |
||||
DUPILUMAB, |
||||
| 535 | 26873981 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 536 | 26874048 |
US |
27 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 537 | 26874105 |
US |
7 | 1 |
Dermatitis atopic, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 538 | 26874118 |
US |
45 | 1 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, TESTOSTERONE CYPIONATE, |
||||
| 539 | 26874207 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 540 | 26874209 |
US |
2 | |
Dermatitis atopic, Sensitivity to weather change, Sunscreen sensitivity, |
||||
DUPILUMAB, |
||||
| 541 | 26874337 |
US |
1 | |
Dermatitis, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 542 | 26874338 |
US |
4 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 543 | 26874343 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 544 | 26874539 |
US |
2 | |
Rash macular, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 545 | 26874544 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 546 | 26874545 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, BIOTIN, BUSPIRONE HYDROCHLORIDE, OLANZAPINE, |
||||
| 547 | 26874555 |
US |
10 | 1 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 548 | 26874732 |
US |
62 | 1 |
Dermatitis atopic, Superficial injury of eye, |
||||
DUPILUMAB, |
||||
| 549 | 26874734 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 550 | 26874739 |
US |
46 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 551 | 26874740 |
US |
23 | 2 |
Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, CETIRIZINE HYDROCHLORIDE, |
||||
| 552 | 26874954 |
US |
9 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 553 | 26875017 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 554 | 26875127 |
US |
29 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 555 | 26867964 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, IRON, |
||||
| 556 | 26868183 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 557 | 26868204 |
US |
10 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 558 | 26868408 |
US |
3 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 559 | 26868422 |
US |
69 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 560 | 26868448 |
EU |
76 | 2 |
Blindness, Alopecia, Dizziness, Pruritus, Pain, Dermatitis atopic, Pustule, Genital pain, |
||||
| 561 | 26868710 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 562 | 26868716 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 563 | 26869096 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 564 | 26869107 |
US |
76 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 565 | 26869117 |
US |
61 | 1 |
Contusion, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 566 | 26869119 |
US |
2 | |
Dermatitis atopic, Product prescribing issue, |
||||
DUPILUMAB, DUPILUMAB, AMLODIPINE BESYLATE, AZELASTINE HYDROCHLORIDE, AZELASTINE, CALCIUM, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, HYDROCHLOROTHIAZIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, ROFLUMILAST, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 567 | 26869403 |
US |
1 | |
Cutaneous T-cell lymphoma stage IV, Anhedonia, Swelling face, Pain, Injury, Anxiety, Emotional distress, Erythema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 568 | 26869423 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 569 | 26869424 |
US |
57 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 570 | 26869428 |
US |
13 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 571 | 26869431 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 572 | 26870011 |
US |
2 | |
Gallbladder operation, Dermatitis atopic, Skin disorder, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 573 | 26870059 |
US |
26 | 1 |
Dermatitis atopic, Perioral dermatitis, |
||||
DUPILUMAB, |
||||
| 574 | 26870224 |
US |
1 | |
Dermatitis atopic, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, |
||||
| 575 | 26870357 |
US |
45 | 2 |
Dermatitis atopic, Ocular hyperaemia, Eye swelling, Eye pruritus, Pruritus, Swelling face, Temperature intolerance, Swelling, Eye pruritus, |
||||
DUPILUMAB, |
||||
| 576 | 26870388 |
US |
23 | 1 |
Feeling hot, Nasal congestion, Dermatitis atopic, Dry skin, Rash, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 577 | 26870406 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 578 | 26870890 |
US |
73 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 579 | 26871334 |
US |
11 | 1 |
Skin erosion, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, FLUOCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 580 | 26871347 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 581 | 26871642 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 582 | 26871673 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 583 | 26871686 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 584 | 26871690 |
US |
61 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 585 | 26872005 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 586 | 26872024 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 587 | 26872248 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, Rash, |
||||
DUPILUMAB, |
||||
| 588 | 26872275 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 589 | 26872479 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 590 | 26862658 |
US |
38 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 591 | 26862662 |
US |
78 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 592 | 26862859 |
US |
24 | 2 |
Platelet count increased, Nasal polyps, Orthopnoea, Back pain, Dermatitis atopic, Rash, Oral herpes, |
||||
DUPILUMAB, ONABOTULINUMTOXINA, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, POVIDONE, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FISH OIL, ROSUVASTATIN CALCIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ERGOCALCIFEROL, |
||||
| 593 | 26862865 |
US |
73 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 594 | 26863072 |
US |
10 | 2 |
Hyperhidrosis, Anxiety, Dermatitis atopic, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 595 | 26863091 |
US |
53 | 1 |
Hyperhidrosis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 596 | 26863120 |
US |
6 | 1 |
Dermatitis atopic, Skin irritation, Dermatillomania, |
||||
DUPILUMAB, |
||||
| 597 | 26863269 |
US |
8 | 1 |
Heavy exposure to ultraviolet light, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 598 | 26863279 |
US |
18 | 1 |
Erythema, Pruritus, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 599 | 26863307 |
US |
65 | 2 |
Dermatitis atopic, Rash, Product prescribing issue, |
||||
DUPILUMAB, |
||||
| 600 | 26863366 |
US |
51 | 1 |
Psoriatic arthropathy, Arthropathy, Dermatitis atopic, Condition aggravated, |
||||
ABATACEPT, ABATACEPT, ABATACEPT, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30